Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress
October 20, 2014 at 08:04 AM EDT
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that data from a Phase 2 trial of its PSMA imaging agent candidate, 1404, ...